Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF).

NCT03129490 is registered in ClinicalTrials.gov with Herlev and Gentofte Hospital as lead sponsor.

NCT NCT03129490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03129490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF).
Lead sponsor
Herlev and Gentofte Hospital
Phase
Phase 4
Overall status
Active, not recruiting
Start date
April 1, 2023
Completion date
October 30, 2027
Enrollment
11,000 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, atrial flutter